©2022 Stanford Medicine
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Recruiting
I'm InterestedTrial ID: NCT03137381
Purpose
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with
chronic, moderate to severe alopecia areata.
Official Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Stanford Investigator(s)
Justin M Ko, MD, MBA
Clinical Professor, Dermatology
Eligibility
Inclusion Criteria:
- Definitive diagnosis of alopecia areata with a current episode lasting at least 6
months and not exceeding 10 years at the time of Screening. Total disease duration
greater than 10 years is permitted.
- At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score
≥50, at Screening and Baseline.
- Clinical lab results within the normal range
Exclusion Criteria:
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
keratosis on the scalp.
- Treatment with systemic immunosuppressive medications or biologics.
- Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening
or during the study
Intervention(s):
drug: CTP-543
drug: CTP-543 matching placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Michelle Kim
650-498-4880